Therapeutical Class：3rd generation cephalosporins, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): not for Enterococci, MRSA, Listeria; G(-): E.coil, Proteus, Providencia, Klebsiella, Enterobacter, Citrobacter, H.influenzae, Serratia variable, not for Acinetobacter and Pseudomonas.

Administraton：IV or IM.

Adults: 1-2 g/day in 1-2 divided doses, max 4 g/day.

Brain abscess and meningitis: 2 g q12h.

Pneumonia, septic arthritis, pyelonephritis: 1-2 g qd.

Concurrent renal and hepatic impairment: not exceed 2 g/day.

Children: 50-100 mg/kg/day in 1-2 divided doses, max 4 g/day.

Adverse Effect：Rash (1-10%), eosinophilia, thrombocytosis, leukopenia, phlebitis, neutropenia, diarrhea (1-10%), nausea, vomiting, thrombocytopenia, elevated AST and BUN.

Contraindication：Hyperbilirubinemic neonates, concurrent administration of calcium-containing solutions in neonates (< 28 days).

Pregnancy Risk：BSupply：Rocephin XE “Rocephin”  Inj 500mg（羅氏芬靜脈注射劑 羅氏）＜01494＞